A Phase 3 interventional study of Diroximel Fumarate and Dimethyl Fumarate in Relapsing Forms of Multiple Sclerosis, sponsored by Biogen. Not yet recruiting. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by Biogen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis — 1 open to participants now, 1 under way, 1 of them phase 3. Dimethyl Fumarate · Multiple Sclerosis.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, this one is the 9th largest by planned enrollment, is the only one that started in 2026, is one of 9 in phase 3, and was the 22nd registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →1 of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis is open now.
Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 185 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 86 across the 22 interventional studies. Of the 17 that completed or were terminated, 11 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 22 have an industry lead sponsor. The 5 most frequent:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
127 studies in Multiple Sclerosis by Biogen: 2 open now, 4 under way, 1 of them phase 3. Of 119 finished, 36 (30%) have results posted.
Among the 127 studies in Multiple Sclerosis by Biogen, this one is the 31st largest by planned enrollment of the 79 interventional ones that give a count, is the only one that started in 2026, is one of 28 in phase 3, and was the 127th registered.
Biogen’s Multiple Sclerosis studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Biogen’s 127 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
In this study, researchers will learn more about the study drugs diroximel fumarate (DRF) and dimethyl fumarate (DMF) in children with MS who may be experiencing relapses.
Participants will be divided into 2 groups based on their weight:
This is a 2-part study. Part 1 treatment will last 96 weeks. Participants who complete Part 1 may move to Part 2. Part 2 is an extension period. Treatment will last another 96 weeks and will help researchers learn about the long-term safety and effects of treatment.
The main goal of the study is to learn about the safety of DRF and DMF and compare their effect on relapses and brain lesions with fingolimod.
The main questions researchers want to answer are:
Researchers will take brain imaging scans to check for any new areas of brain inflammation and compare the brain lesions before and after treatment.
Researchers will also measure the amount of drug in the blood to understand how the body processes it. To check safety, they will monitor participants' growth and development, and compare changes in heart tests, vital signs, and lab tests. They will also use rating scales to monitor depression symptoms.
The study will be done as follows:
Part 1 (Treatment Period)
Part 2 (Extension Period)
The primary objectives of this study are to evaluate the safety, tolerability of diroximel fumarate (DRF), the noninferiority of the clinical efficacy of monomethyl fumarate (MMF) (pooled DRF and dimethyl fumarate [DMF] treatment) compared to that of fingolimod and long-term safety and tolerability of DRF in participants who completed Week 96 of the Treatment Period. The secondary objectives of this study are to characterize the pharmacokinetic (PK) profile of DRF metabolites (MMF and 2-hydroxyethyl succinimide [HES]), additional safety and tolerability of DRF, noninferiority of the radiological efficacy of MMF (pooled DRF and DMF treatment) compared to that of fingolimod, and to further describe the safety and long-term multiple sclerosis (MS) outcomes of DRF in participants who completed Week 96 of the Treatment Period.
Key Inclusion Criteria:
Treatment Period:
Must have experienced at least 1 of the following conditions:
Open-Label Extension Period:
- Participants who completed the study treatment in Cohorts A or B through the Week 96 Visit.
Key Exclusion Criteria
Treatment Period:
Open-Label Extension Period:
NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants weighing ≤ 40 kilograms (kg) will receive DRF 231 milligrams (mg) orally, once daily (QD) (starting dose) on Days 1 to 7 followed by DRF 231 mg orally, BID (twice daily) (maintenance dose) on Day 8 through Week 96.
Drug: Diroximel Fumarate
Participants weighing \>40 kg will receive DRF/placebo matching fingolimod 231 mg orally, BID (starting dose) on Days 1 to 7 followed by DRF 462 mg orally, BID (maintenance dose) on Day 8 through Week 96.
Drug: Diroximel Fumarate · Drug: Placebo matching fingolimod
Participants weighing \>40 kg will receive Fingolimod 0.5 mg orally, QD followed by placebo matching DRF 231 mg (starting dose) orally, BID on Days 1 to 7 followed by placebo matching DRF 462 mg (maintenance dose) orally, BID on Day 8 through Week 96.
Drug: Fingolimod · Drug: Placebo matching DRF
Participants weighing \>40 kg will receive DMF/placebo matching fingolimod 120 mg (starting dose) orally, BID on Days 1 to 7 followed by DMF 240 mg (maintenance dose) orally BID, on Day 8 through Week 96.
Drug: Dimethyl Fumarate · Drug: Placebo matching fingolimod
Participants weighing \>40 kg will receive Fingolimod 0.5 mg oral QD followed by placebo matching DMF 120 mg (starting dose) orally, BID on Days 1 to 7 followed by placebo matching DMF 240 mg (maintenance dose) orally, BID through Week 96.
Drug: Fingolimod · Drug: Placebo matching DMF
Participants from Cohort A weighing ≤ 40 kg will receive DRF 231 mg orally, BID and participants weighing \>40 kg will receive DRF 462 mg orally, BID up to 192 weeks.
Drug: Diroximel Fumarate
Participants from Cohort B will receive DRF 231 mg orally, BID for 7 days, followed by the maintenance dose of DRF 462 mg orally, BID up to 192 weeks.
Drug: Diroximel Fumarate
Oral capsule
Also known as: Vumerity, BIIB098, ALK8700
Oral capsule
Also known as: Tecfidera, BG00012
Oral capsule
Also known as: Gilenya
Oral capsule
Oral capsule
Oral capsule
TP Cohort A and OLE Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and AEs Leading to Treatment Discontinuation
Time frame: Cohort A: From first dose of study drug up to end of follow-up (up to Week 104), OLE: Baseline (Week 96) up to the end of OLE period (up to Week 196)
TP Cohort B: Annualized Relapse Rate (ARR) Through Week 96
Time frame: Baseline (Day 1) up to Week 96
TP Cohorts A and B: Maximum Observed Concentration at Steady State (Cmax,ss) of Monomethyl Fumarate (MMF)
Time frame: Predose and at multiple timepoints post dose up to Week 96
TP Cohorts A and B: Minimum Observed Concentration at Steady State (Cmin,ss) of MMF
Time frame: Predose and at multiple timepoints post dose up to Week 96
TP Cohorts A and B: Cmax,ss of 2-Hydroxyethyl Succinimide (HES)
Time frame: Predose and at multiple timepoints post dose up to Week 96
TP Cohorts A and B: Cmin,ss of HES
Time frame: Predose and at multiple timepoints post dose up to Week 96
TP Cohorts A, B and OLE Period: Number of Participants with Potentially Clinically Serious (PCS) Change from Baseline in Vital Sign Parameters
Time frame: Cohorts A and B: Baseline up to Week 96, OLE: Baseline (Week 96) up to Week 196
TP Cohorts A, B and OLE Period: Number of Participants With Change From Baseline in Clinically Relevant Electrocardiogram (ECG) Abnormalities
Time frame: Cohorts A and B: Baseline up to Week 96, OLE: Baseline (Week 96) up to Week 196
TP Cohorts A, B and OLE Period: Number of Participants with PCS Change from Baseline in Clinical Laboratory Parameters
Time frame: Cohorts A and B: Baseline up to Week 96, OLE: Baseline (Week 96) up to Week 196
TP Cohorts A, B and OLE Period: Change From Baseline in Height
Time frame: Cohorts A and B: Baseline up to Week 104, OLE: Baseline (Week 96) up to Week 196
TP Cohorts A, B and OLE Period: Change From Baseline in Weight
Time frame: Cohorts A and B: Baseline up to Week 104, OLE: Baseline (Week 96) up to Week 196
TP Cohorts A, B and OLE Period: Change From Baseline in Tanner Score
Assessment of Tanner stage will be performed by a healthcare professional experienced with this assessment. Tanner score ranges from Stage 1 (childhood) to Stage 5 (full physical maturity). Information regarding Tanner staging will be collected for all male participants with bone age \< 16 years and for female participants who are premenarche and have a bone age of \< 16 years and will be stopped once the participant's bone age reaches ≥ 16 years or once the participant is postmenarche.
Time frame: Cohorts A and B: Baseline up to Week 96, OLE: Baseline (Week 96) up to Week 196
TP Cohorts A, B and OLE Period: Change From Baseline in Bone Age
Time frame: Cohorts A and B: Baseline up to Week 96, OLE: Baseline (Week 96) up to Week 196
TP Cohorts A, B and OLE Period: Number of Participants with Change From Baseline in Endocrine Tests
Endocrine parameters to be tested will include insulin-like growth factor 1, and insulin-like growth factor binding protein for both females and males; follicle stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E-2) for females; and testosterone, FSH, and LH for males. All endocrine tests will stop being performed once the participant has reached a bone age of ≥ 16 years or the participant is postmenarche.
Time frame: Cohorts A and B: Baseline up to Week 96, OLE: Baseline (Week 96) up to Week 196
TP Cohorts A, B and OLE Period: Change From Baseline in Depression Monitored Using the Children's Depression Rating Scale for Participants <18 Years or the Hamilton Rating Scale for Depression (HAMD-17) for Participants ≥18 Years
Time frame: Cohorts A and B: Baseline up to Week 96, OLE: Baseline (Week 96) up to Week 196
TP Cohorts A, B and OLE Period: Change From Baseline in Depression Monitored Using the Columbia Suicide Severity Rating Scale (C-SSRS)
The C-SSRS is an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assesses whether participant experiences any of the following 1. completed suicide, 2. suicide attempt (response of "yes" on "actual attempt"), 3. preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4. any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent"), 5. self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior").
Time frame: Cohorts A and B: Baseline up to Week 96, OLE: Baseline (Week 96) up to Week 196
TP Cohort B: Change From Baseline in Annualized Rate of New/Newly Enlarging (N/NE) T2 Hyperintense Lesions Through Week 96
Time frame: Baseline (Day 1) up to Week 96
TP Cohort B: Time to First Relapse
Time frame: Baseline (Day 1) up to Week 96
TP Cohort B: Percentage of Participants Free of Relapse up to Week 96
Time frame: Baseline (Day 1) up to Week 96
TP Cohort B and OLE Period: Change From Baseline in Expanded Disability Status Scale (EDSS) Score
The EDSS is a method of quantifying disability and monitoring changes in the level of disability over time. EDSS score ranges from 0 (normal neurological exam) to 10 (death from MS) with higher scores indicating more disability.
Time frame: Cohort B: Baseline up to Week 96, OLE: Baseline (Week 96) up to Week 196
TP Cohort B: Change From Baseline in Number of N/NE T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans at Weeks 48 and 96
Time frame: Baseline up to Weeks 48 and 96
TP Cohort B: Number of Gadolinium (Gd)-Enhancing Lesions on Brain MRI Scans at Baseline and at Weeks 48 and 96
Time frame: At Baseline, Weeks 48 and 96
TP Cohort B: Number of Participants With T1 Hypointense Lesions at Week 96
Time frame: At Week 96
TP Cohort B: Change From Baseline in Percentage of Participants Free of N/NE T2 Hyperintense Lesions on Brain MRI Scans at Weeks 24, 48, and 96
Time frame: Baseline up to Weeks 24, 48, and 96
TP Cohort B: Change From Baseline in Percentage of Participants Free of New MRI Activity at Weeks 24, 48, and 96
Free of new MRI activity is defined as free of Gd-enhancing lesions and free of N/NE T2 MRI lesions on brain MRI scans.
Time frame: Baseline up to Weeks 24, 48, and 96
TP Cohort B: Number of Participants With TEAEs, SAEs and AEs Leading to Treatment Discontinuation
Time frame: From first dose of study drug up to end of follow-up (up to Week 104)
OLE Period: ARR at Weeks 144 and 192
Time frame: At Weeks 144 and 192
No study locations are listed for this record.
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jul 2034, 92 months later.
Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's planned 92 months is above that.
Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Diroximel fumarate · Dimethyl Fumarate · Fingolimod